Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Curcumin BioBDMC30 is a patented curcumin extract with an exceptionally high concentration of bisdemethoxycurcumin (BDMC), typically at 30% compared to the 0.5–1.5% found in standard curcumin extracts. This enhanced formulation is designed for faster and more effective anti-inflammatory results by targeting key proteins involved in inflammation at the genetic and subcellular level. Specifically, BDMC inhibits both NF-kB and MSK1 proteins—regular curcumin only inhibits NF-kB—providing a dual mechanism for combating inflammation[1][5][6]. The product also exhibits extremely high antioxidant activity as measured by ORAC value (oxygen radical absorbance capacity), far exceeding that of regular curcumin[1][5]. It is marketed for managing inflammation, joint pain, discomfort, supporting recovery from injuries or workouts, and promoting cognitive health due to its ability to reduce brain inflammation[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Curcumin BioBDMC30.